Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Cancer Research

• Publication date

  2015-05-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-15-0244PMID 25944800PMCID PMC4558237
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

  2015influential reference
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014influential reference
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014influential reference
• Interleukin-32 Increases Human Gastric Cancer Cell Invasion Associated with Tumor Progression and Metastasis

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

  2013influential reference
• Current status of interleukin-10 and regulatory T-cells in cancer

  2013cited by this paper
• IL-32 with potential insights into rheumatoid arthritis.

  2013cited by this paper
• Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.

  2013cited by this paper
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012influential reference
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Immunotherapy earns its spot in the ranks of cancer therapy

  2012cited by this paper
• Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

  2010cited by this paper
• Identification of the most active interleukin‐32 isoform

  2009cited by this paper
• Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

  2008cited by this paper
• Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

  2008cited by this paper
• Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays.

  2004cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion

  2000influential reference
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.

  1994cited by this paper
• Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

  year unknowncited by this paper

• Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors.

  2026cites this paper
• LAG-3 in (auto)immunity and cancer - Emphasising its role in antigen presenting cells.

  2026cites this paper
• Platelets in the tumor microenvironment: potential mediators of immune exclusion and resistance to immune checkpoint inhibitor therapy

  2026cites this paper
• Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy

  2025cites this paper
• Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles

  2025cites this paper
• Helicobacter pylori is associated with less tumor-infiltrating lymphocytes and a poor prognosis in gastric cancer

  2025cites this paper
• Cervical cancer molecular subtype identification and prognosis classification by a metabolism-related gene expression

  2025cites this paper
• Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data

  2025cites this paper
• A New Light-Sensor System Affecting Cancer Cell Fate

  2025cites this paper
• A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

  2025cites this paper
• Identification of Prognostic and Diagnostic Biomarkers for Glioma Utilizing Immune System Gene Profiling

  2025cites this paper
• Advances and future directions in radiopharmaceutical delivery for cancer treatment

  2025cites this paper
• Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the molecular feature of tumor-associated neutrophils of head and neck squamous cell carcinoma

  2025cites this paper
• First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors

  2025cites this paper
• Protein post-translational modifications and tumor immunity: A pan-cancer perspective.

  2025cites this paper
• The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status

  2024cites this paper
• KRas plays a negative role in regulating IDO1 expression

  2024cites this paper
• Impacts of Interleukin-10 Promoter Genotypes on Prostate Cancer

  2024cites this paper
• Perforin 1 in Cancer: Mechanisms, Therapy, and Outlook

  2024cites this paper
• Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma

  2024cites this paper
• Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review

  2024cites this paper
• Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects

  2024cites this paper
• Prognostic significance of CD8 and TCF1 double positive T cell subset in microsatellite unstable gastric cancer

  2024cites this paper
• The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review

  2024cites this paper
• Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer

  2023cites this paper
• CD3ζ as a novel predictive biomarker of PD-1 inhibitor resistance in melanoma.

  2023cites this paper
• Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade

  2023cites this paper
• Programmed cell death‐1 blockade therapy in melanoma: Resistance mechanisms and combination strategies

  2023cites this paper
• Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression

  2023cites this paper
• HNF4α, SP1 and c-myc are master regulators of CNS autoimmunity.

  2023cites this paper
• Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78

  2023cites this paper
• Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)

  2023cites this paper
• From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma

  2023cites this paper
• Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

  2023influential citation
• Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors

  2023cites this paper
• The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma

  2023cites this paper
• Four Immune Modulating Genes in Primary Melanoma That Predict Metastatic Potential

  2022cites this paper
• LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors

  2022cites this paper
• The Association of Programmed Death-Ligand 1 Expression with Clinicopathological Features, Lymph Node Metastasis and Survival Prognosis in Patients with Colorectal Carcinoma

  2022cites this paper
• Xenogeneic Sertoli cells modulate immune response in an evolutionary distant mouse model through the production of interleukin‐10 and PD‐1 ligands expression

  2022cites this paper
• Regulation of Intrinsic Functions of PD-L1 by Post-Translational Modification in Tumors

  2022cites this paper
• Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma

  2022cites this paper
• A Paradoxical Effect of Interleukin-32 Isoforms on Cancer

  2022cites this paper
• Programmed Death Ligand 1 (PD-L1) Expression and CD8+ Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy

  2022cites this paper
• Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.

  2022cites this paper
• LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance

  2022cites this paper
• Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.

  2022cites this paper
• Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases

  2022cites this paper
• Immunogenetics: a tool for anthropological studies

  2022cites this paper
• Clinical Insights Into Novel Immune Checkpoint Inhibitors

  2021influential citation
• Tumor Spheroids of an Aggressive Form of Central Neurocytoma Have Transit-Amplifying Progenitor Characteristics with Enhanced EGFR and Tumor Stem Cell Signaling

  2021cites this paper
• Underlying mechanisms and drug intervention strategies for the tumour microenvironment

  2021cites this paper
• Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects

  2021cites this paper
• Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

  2021cites this paper
• PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients

  2021cites this paper
• Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues

  2021cites this paper
• Elevated peripheral absolute monocyte count related to clinicopathological features and poor prognosis in solid tumors: Systematic review, meta‐analysis, and meta‐regression

  2021cites this paper
• Single-cell melanoma transcriptomes depicting functional versatility and clinical implications of STIM1 in the tumor microenvironment

  2021influential citation
• IFN-γ and CD38 in Hyperprogressive Cancer Development

  2021cites this paper
• Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes

  2021cites this paper
• Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis

  2021influential citation
• Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

  2021cites this paper
• Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells

  2021cites this paper
• OTT_A_283892 5275..5291

  2021cites this paper
• High Expression of TIM 3 and Galectin 9 on Immunohistochemistry Staining of Tumor Specimen at Diagnosis in Pediatric Patients with Ewing Sarcoma

  2021cites this paper
• Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer

  2021cites this paper
• Mechanism of Carcinogenesis and Progression

  2021cites this paper
• Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer

  2021cites this paper
• Predictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors

  2021cites this paper
• Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance

  2021cites this paper
• Promising potential of a 18F-labelled small-molecular radiotracer to evaluate PD-L1 expression in tumors by PET imaging.

  2021cites this paper
• Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?

  2021cites this paper
• Прогностические биомаркеры эффективности иммунотерапии злокачественных новообразований ингибиторами контрольных точек иммунного ответа

  2021cites this paper
• 9-Gene Signature Correlated With CD8+ T Cell Infiltration Activated by IFN-γ: A Biomarker of Immune Checkpoint Therapy Response in Melanoma

  2021cites this paper
• Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis

  2021cites this paper
• Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells

  2021cites this paper
• Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma

  2021cites this paper
• Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients

  2021cites this paper
• Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications

  2021influential citation
• Next-Generation Immunotherapy Approaches in Melanoma

  2021cites this paper
• Functional responses of resident human T cells in intact liver tissue.

  2020cites this paper
• Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.

  2020cites this paper
• Prediction of a competing endogenous RNA co‐expression network as a prognostic marker in glioblastoma

  2020cites this paper
• The Association of Residential Altitude on the Molecular Profile and Survival of Melanoma: Results of an Interreg Study

  2020cites this paper
• LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma

  2020cites this paper
• Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers

  2020cites this paper
• Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges

  2020influential citation
• NF-κB and Its Role in Checkpoint Control

  2020cites this paper
• Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma

  2020cites this paper
• FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

  2020cites this paper
• Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation

  2020cites this paper
• The Primary Tumor Immune Microenviornment Status Predicts the Response to Immunotherapy and Overall Survival in Breast Cancer

  2020cites this paper
• Identification of Co-Expressed Genes Promoting CD8+ T Cell Infiltration in Melanoma Tumor Microenvironments

  2020cites this paper
• Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer

  2020cites this paper
• Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T

  2020cites this paper
• Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?

  2020cites this paper
• The G protein coupled receptor CCR5 in cancer.

  2020cites this paper
• Determinants of Resistance to Checkpoint Inhibitors

  2020cites this paper
• Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.

  2020cites this paper
• PD‐L1 and LAG‐3 expression in advanced cutaneous squamous cell carcinomas

  2020cites this paper